Skip to main content
No. of Recommendations: 21
BMR is a solid REIT. They own and lease space to life science companies, primarly pharma and biotech. This is a very good property sector, and is less economically-sensitive than most. Owners do, however, need to exercise care in tenant choice. BMR is less concentrated in "cluster" markets where the major tenants want to be, but their markets are solid and have been able to keep occupancies at good levels.

I do not like them as well as ARE, their only true public company peer. I prefer ARE's locations and think they will create more shareholder value over time. But BMR is doing pretty well, and should continue to do so. I think the stock has been weak recently due to a change in management (although not their top guy), and because of questions concerning near-term portfolio performance.

The stock is cheap on an NAV and dividend yield basis and, while total returns may not be as good as ARE's going forward, earnings growth should resume next year. And the balance sheet is strong, at below 40% total leverage. BMR is particularly attractive for those who want a higher yield with only modest risk, although it could be an underperformer for a while longer. I own it, in modest proportions.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.